PROCEPT BioRobotics (MEX:PRCT) Retained Earnings: MXN-12,140 Mil (As of Mar. 2026)


MEX:PRCT PROCEPT BioRobotics Corp MEX:PRCT
54 GF Score
Price MXN358.45
GF Value MXN1,463.67
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is PROCEPT BioRobotics Retained Earnings?

PROCEPT BioRobotics MEX:PRCT 54 Retained Earnings is MXN-12,140 Mil as of Mar. 2026. GuruFocus rates MEX:PRCT with a GF Score™ of 54/100 and a GF Value™ of MXN1,463.67 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. PROCEPT BioRobotics's retained earnings for the quarter that ended in Mar. 2026 was MXN-12,140 Mil.

PROCEPT BioRobotics's quarterly retained earnings declined from Sep. 2025 (MXN-11,221 Mil) to Dec. 2025 (MXN-11,552 Mil) and declined from Dec. 2025 (MXN-11,552 Mil) to Mar. 2026 (MXN-12,140 Mil).

PROCEPT BioRobotics's annual retained earnings declined from Dec. 2023 (MXN-7,716 Mil) to Dec. 2024 (MXN-11,387 Mil) and declined from Dec. 2024 (MXN-11,387 Mil) to Dec. 2025 (MXN-11,552 Mil).


PROCEPT BioRobotics  (MEX:PRCT) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


PROCEPT BioRobotics Retained Earnings Historical Data

* Premium members only.

The historical data trend for PROCEPT BioRobotics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PROCEPT BioRobotics Retained Earnings Chart

PROCEPT BioRobotics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial -5,364.84 -6,797.77 -7,716.02 -11,386.90 -11,551.68

PROCEPT BioRobotics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11,675.95 -11,114.88 -11,221.35 -11,551.68 -12,139.52
MEX:PRCT
54GF Score
PROCEPT BioRobotics Corp MEX:PRCT
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PROCEPT BioRobotics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of MXN-12,140 Mil mean?
PROCEPT BioRobotics (MEX:PRCT) has a Retained Earnings of MXN-12,140 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on PROCEPT BioRobotics and its competitors.
Is PROCEPT BioRobotics' Retained Earnings too high?
PROCEPT BioRobotics' current Retained Earnings is MXN-12,140 Mil. Overall, PROCEPT BioRobotics has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Retained Earnings compare to ALMR and AHCO?
PROCEPT BioRobotics' Retained Earnings of MXN-12,140 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on PROCEPT BioRobotics and its competitors. PROCEPT BioRobotics's current Retained Earnings is MXN-12,140 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (MEX:PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,463.67, compared to a current price of MXN358.45 — trading 75.5% below its estimated fair value. The current Retained Earnings is MXN-12,140 Mil. PROCEPT BioRobotics' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For PROCEPT BioRobotics (MEX:PRCT), the current Retained Earnings is MXN-12,140 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROCEPT BioRobotics (MEX:PRCT) Overvalued in 2026?

Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued. The current stock price of MXN358.45 is trading 75.5% below its estimated GF Value™ of MXN1,463.67. GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.

Key valuation signals for MEX:PRCT:

  • Retained Earnings: MXN-12,140 Mil
  • GF Value™: MXN1,463.67 vs. price of MXN358.45 (75.5% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the MEX:PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PROCEPT BioRobotics Business Description

Other Exchanges PRCT:USA
Address 150 Baytech Drive, San Jose, CA, USA, 95134
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
54GF Score

Get the complete analysis for MEX:PRCT

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN358.45
Price
MXN1,463.67
GF Value